ClinicalTrials.Veeva

Menu

A Prospective Study of Different Digoxin Treatment Regimens in Egyptian Hospital

Cairo University (CU) logo

Cairo University (CU)

Status and phase

Completed
Phase 4

Conditions

Atrial Fibrillation

Treatments

Drug: digoxin dose is calculated using Jusko-Koup method and given daily
Drug: patients take 0.25 mg of digoxin daily except thursday and friday
Drug: patients take 0.25 mg of digoxin daily except friday
Drug: patients take 0.125 mg of digoxin daily

Study type

Interventional

Funder types

Other

Identifiers

NCT02489786
CL (312)

Details and patient eligibility

About

Digoxin is the primary cardiac glycoside in clinical use. Because of the narrow therapeutic index and risk of toxicity, therapeutic drug monitoring is highly recommended. In Egypt, most cardiologists give digoxin holiday for both atrial fibrillation and heart failure, it is not clear if the interrupted digoxin regimens are effective since serum digoxin concentrations might fall below the therapeutic range.

Objective: To evaluate and compare the digoxin serum concentration and patient's quality of life in the continuous versus interrupted digoxin dosing regimens.

Full description

Digoxin is a cardiac glycoside prescribed in heart failure and certain supraventricular tachyarrhythmias. It exerts a positive inotropic, neurohormonal, and electro physiologic actions on the heart . For heart failure patients, the targeted steady state serum digoxin level is between 0.5 and 0.8 ng/ml . Ventricular rate control in atrial fibrillation patients will usually require higher digoxin steady state serum concentrations . However, serum digoxin level higher than 2 ng/ml is associated with increased incidence of adverse drug reactions and should be avoided . Because of inter and intra-patient variability, narrow therapeutic index, and risk of toxicity, digoxin doses are calculated based on the patient weight, renal status, indications and drug interactions. Due to substantial overlap between therapeutic and toxic levels of digoxin, therapeutic drug monitoring is a must especially in patients with deteriorating renal function and electrolyte disturbance. In Egypt, most cardiologists give a digoxin holiday for patients with atrial fibrillation and /or heart failure where patients skip the drug doses on Thursday and Friday or Friday only every week to avoid possible drug accumulation and toxicity. It is not clear if these interrupted digoxin regimens really offer safer alternative over the continuous dosing regimens without compromising the effectiveness. It is anticipated that plasma digoxin levels may fall below the therapeutic range during the holiday which may affect patient clinical status and quality of life.

Enrollment

71 patients

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients with atrial fibrillation (AF)
  • with or without congestive heart failure (CHF)
  • taking digoxin tablets with or without holiday regimens

Exclusion criteria

  • taking the following drugs concurrently: amiodarone, verapamil, quinidine and propafenone.
  • diagnosed with thyroid disorders (hyperthyroidism & hypothyroidism).
  • diagnosed with renal failure
  • pregnant

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

71 participants in 4 patient groups

Regimen 1
Active Comparator group
Description:
patient takes 0.25mg of digoxin daily except friday
Treatment:
Drug: patients take 0.25 mg of digoxin daily except friday
Regimen 2
Active Comparator group
Description:
patient takes 0.25mg of digoxin daily except Thursday and Friday
Treatment:
Drug: patients take 0.25 mg of digoxin daily except thursday and friday
Regimen 3
Active Comparator group
Description:
patient takes 0.125mg of digoxin daily
Treatment:
Drug: patients take 0.125 mg of digoxin daily
Regimen 4
Active Comparator group
Description:
digoxin dose is calculated using Jusko-Koup method and given daily
Treatment:
Drug: digoxin dose is calculated using Jusko-Koup method and given daily

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems